Drug Trial News

RSS

Pralatrexate shows promise for T-Cell lymphoma

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

10 Dec 2008

Rosiglitazone shows potential for treating focal segmental glomerulosclerosis

The antidiabetes drug rosiglitazone may have the potential to protect kidney function in patients with a condition called focal segmental glomerulosclerosis (FSGS), according to a study appearing in the January 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN).

10 Dec 2008

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

VIDAZA (azacitidine) study reports survival benefit in higher-risk MDS extends to AML patients

Celgene International Sàrl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extended to patients with acute myeloid leukemia (AML).

10 Dec 2008

DNA vaccine for SARS achieves neutralizing responses in first U.S. human trial

Vical Incorporated (NASDAQ:VICL) today announced that results from a Phase I clinical trial of a DNA vaccine for severe acute respiratory syndrome (SARS), conducted by the National Institutes of Health (NIH) and published in the November 25 issue of Vaccine(1), demonstrated that the vaccine was well-tolerated, and induced neutralizing antibody responses in 80% of the vaccinees and T-cell immune responses in all vaccinees.

10 Dec 2008

Potential breakthrough for T-cell lymphoma

10 Dec 2008

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

Pycnogenol reduces inflammatory marker C-reactive protein in osteoarthritis

Osteoarthritis (OA), a type of arthritis caused by the breakdown and loss of cartilage, affects more than 20 million Americans.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

$EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients$

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.

10 Dec 2008

Dacogen data presented on trial in seniors with acute myeloid leukemia

Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.

10 Dec 2008

Cholinesterase inhibitors safe and effective therapy for behavioral and psychological symptoms of dementia

Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears in the December 2008 edition of Clinical Interventions in Aging.

10 Dec 2008

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AstraZeneca and Targacept, Inc. havey announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

10 Dec 2008

AcelRx Pharmaceuticals reports positive results in trial of sublingual Sufentanil NanoTabs in treating post-op pain

AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery.

10 Dec 2008

Positive trial results for transdermal Lidocaine system

Phosphagenics Limited has announced the successful completion of a phase 1 clinical trial that examined the ability of its patented drug delivery system, TPM, to topically deliver the pain relief drug, lidocaine, safely into humans.

8 Dec 2008

Older patients with acute myloid leukemia patients show promising response in drug study

Older patients with acute myloid leukemia (AML) who were once told that nothing could be done for them are finding new hope - and life - through a clinical trial at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

8 Dec 2008

Participants in clinical trials value personalized, accurate information about study results

Participants in clinical trials report being satisfied with personalized, accurate communication of results by study investigators soon after the study findings are released publicly, according to a report in the December issue of Archives of Neurology.

8 Dec 2008

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).

8 Dec 2008

Novel approach to disseminate trial results to study volunteers

While an estimated 2.3 million people in the U.S. take part in clinical trials every year, there currently exists no formal requirement to inform them of study results; an oversight that leaves participants confused, frustrated, and, in some cases, lacking information that may be important to their health.

8 Dec 2008

Drug Trial News

Pralatrexate shows promise for T-Cell lymphoma

Rosiglitazone shows potential for treating focal segmental glomerulosclerosis

Xencor presents data on anti-CD19 and anti-CD40 antibodies

VIDAZA (azacitidine) study reports survival benefit in higher-risk MDS extends to AML patients

DNA vaccine for SARS achieves neutralizing responses in first U.S. human trial

Potential breakthrough for T-cell lymphoma

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Pycnogenol reduces inflammatory marker C-reactive protein in osteoarthritis

New data on ZOLINZA (vorinostat) in combination with Bortezomib

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

Dacogen data presented on trial in seniors with acute myeloid leukemia

Cholinesterase inhibitors safe and effective therapy for behavioral and psychological symptoms of dementia

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AcelRx Pharmaceuticals reports positive results in trial of sublingual Sufentanil NanoTabs in treating post-op pain

Positive trial results for transdermal Lidocaine system

Older patients with acute myloid leukemia patients show promising response in drug study

Participants in clinical trials value personalized, accurate information about study results

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Novel approach to disseminate trial results to study volunteers

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News